All News

Ireland’s new Biomedical Diagnostics Institute was launched last week as the focus for industrial-clinical-academic research collaborations.

The UK is setting up a national network to carry out clinical trials of paediatric medicines, filling the gap left by pharmaceutical companies which usually test drugs only on adults.

Seven partners have teamed up with €2.4 million in EU backing to develop a vaccine against Alzheimer’s disease.

Transport | Aviation | Energy | Airbus | United Kingdom

For European tech start-ups, 2006 was the year that the traffic lights for money switched from red to yellow. Yet to be seen is whether they finally go green next year.

The EU is meant to be good at compromise. Not so on patents. As the latest compromise bit the dust, Commissioner McCreevy promised to have one, last, go.

Liquavista BV, a fabless display manufacturing company, has raised €12 million in a first-round funding led by Amadeus Capital Partners and GIMV.

A plan to build the science base in European countries that lag behind got under way with the award of the first round of grants to enable young researchers to relocate.

Pharminox Ltd, a private oncology R&D company backed by IP Group, is to carry out joint research into novel small molecule chemotherapeutics with Schering-Plough.

Anglo-Dutch antibody specialist PanGenetics BV has agreed a collaboration with Lay Line Genomics SpA of Rome, Italy, in the field of therapeutic antibodies for the treatment of pain.

Cambridge Biostability, a developer of temperature-stable liquid vaccines, agreed a joint venture with Panacea Biotec of India.

Galapagos NV is bolstering its ability to select drug targets and compounds by acquiring Inpharmatica Ltd in an all-share transaction that values the UK bioinformatics company at €12.5 million.

In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out.

A conference in Brussels separates the fact from myth in technology transfer.